Brief Report: Medication Sharing Is Rare Among African HIV-1 Serodiscordant Couples Enrolled in an Efficacy Trial of Oral Pre-exposure Prophylaxis (PrEP) for HIV-1 Prevention. (1st June 2017)

• Record Type: Journal Article
• Authors: Thomson, Kerry A.; Haberer, Jessica E.; Marzinke, Mark A.; Mujugira, Andrew; Hendrix, Craig W.; Celum, Connie; Ndase, Patrick; Ronald, Allan; Bangsberg, David R.; Baeten, Jared M.
• Is Part Of: Journal of acquired immune deficiency syndromes. Volume 75:Number 2(2017)
• Publication Date: 2017-06-01
• Subjects: HIV-1 -- pre-exposure prophylaxis -- HIV-1 serodiscordant couples -- adherence -- prescription drug diversion; AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome -- Periodicals; AIDS (Disease); Periodicals; 616.9792005
• DOI: 10.1097/QAI.0000000000001356
• Languages: English
• ISSNs: 1525-4135

Abstract

Abstract : Abstract: Sharing of pre-exposure prophylaxis (PrEP) medications is a concern for PrEP implementation. For HIV-1 serodiscordant couples, sharing may undermine the HIV-1 prevention benefit and also cause antiretroviral resistance if taken by HIV-1 infected partners. Within a PrEP efficacy trial among HIV-1 serodiscordant couples, we assessed the occurrence of PrEP sharing by self-report and plasma tenofovir concentrations in HIV-1 infected partners. PrEP sharing was self-reported at <0.01% of visits, and 0%–1.6% of randomly selected and 0% of purposively selected specimens from HIV-1 infected participants had detectable tenofovir concentrations (median: 66.5 ng/mL, range: 1.3–292 ng/mL). PrEP sharing within HIV-1 serodiscordant couples was extremely rare.